Weekly insulin shot could replace daily jabs for diabetes
NCT ID NCT06767748
First seen Nov 21, 2025 · Last updated Jun 20, 2026 · Updated 25 times
Summary
This phase 3 study tests a new insulin called GZR4 that is injected just once a week, compared to the standard daily insulin degludec. About 620 adults with type 2 diabetes who already use basal insulin will take part. The goal is to see if the weekly shot controls blood sugar just as well, with similar safety and fewer injections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Gan & Lee Pharmaceuticals Shandong Co., Ltd.
Linyi, Shandong, 276000, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GZR4 (a once-weekly insulin injection)
What this could lead to
If it works, this could offer a more convenient once-weekly insulin option for people with type 2 diabetes, reducing daily injections.
What could go wrong
This is a phase 3 trial, but it's still experimental. The new insulin may not control blood sugar as well as daily insulin, or could cause different side effects like hypoglycemia or weight changes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.